Skip to main content
Journal cover image

Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry.

Publication ,  Journal Article
Beukelman, T; Lougee, A; Matsouaka, RA; Collier, D; Rumsey, DG; Schenfeld, J; Stryker, S; Twilt, M; Kimura, Y; CARRA Registry Investigators,
Published in: Pediatr Rheumatol Online J
August 21, 2021

BACKGROUND: We aimed to characterize etanercept (ETN) use in juvenile idiopathic arthritis (JIA) patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry. METHODS: The CARRA Registry is a convenience cohort of patients with paediatric onset rheumatic diseases, including JIA. JIA patients treated with ETN for whom the month and year of ETN initiation were available were included. Patterns of ETN and methotrexate (MTX) use were categorized as follows: combination therapy (ETN and MTX started concurrently), step-up therapy (MTX started first and ETN added later), switchers (MTX started and then stopped when or before ETN started), MTX add-on (ETN started first and MTX added later), and ETN only (no MTX use). Data were described using parametric and non-parametric statistics as appropriate. RESULTS: Two thousand thirty-two of the five thousand six hundred forty-one patients with JIA met inclusion criteria (74% female, median age at diagnosis 6.0 years [interquartile range 2.0, 11.0]. Most patients (66.9%) were treated with a non-biologic disease modifying anti-rheumatic drug (DMARD), primarily MTX, prior to ETN. There was significant variability in patterns of MTX use prior to starting ETN. Step-up therapy was the most common approach. Only 34.0% of persistent oligoarticular JIA patients continued treatment with a non-biologic DMARD 3 months or more after ETN initiation. ETN persistence overall was 66.3, 49.4, and 37.3% at 24, 36 and 48 months respectively. ETN persistence among spondyloarthritis patients (enthesitis related arthritis and psoriatic JIA) varied by MTX initiation pattern, with higher ETN persistence rates in those who initiated combination therapy (68.9%) and switchers/ETN only (73.3%) patients compared to step-up (65.4%) and MTX add-on (51.1%) therapy. CONCLUSION: This study characterizes contemporary patterns of ETN use in the CARRA Registry. Treatment was largely in keeping with American College of Rheumatology guidelines.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Pediatr Rheumatol Online J

DOI

EISSN

1546-0096

Publication Date

August 21, 2021

Volume

19

Issue

1

Start / End Page

131

Location

England

Related Subject Headings

  • United States
  • Tumor Necrosis Factor Inhibitors
  • Registries
  • Methotrexate
  • Medication Therapy Management
  • Male
  • Immunosuppressive Agents
  • Humans
  • Female
  • Etanercept
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Beukelman, T., Lougee, A., Matsouaka, R. A., Collier, D., Rumsey, D. G., Schenfeld, J., … CARRA Registry Investigators, . (2021). Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry. Pediatr Rheumatol Online J, 19(1), 131. https://doi.org/10.1186/s12969-021-00625-y
Beukelman, Timothy, Aimee Lougee, Roland A. Matsouaka, David Collier, Dax G. Rumsey, Jennifer Schenfeld, Scott Stryker, Marinka Twilt, Yukiko Kimura, and Yukiko CARRA Registry Investigators. “Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry.Pediatr Rheumatol Online J 19, no. 1 (August 21, 2021): 131. https://doi.org/10.1186/s12969-021-00625-y.
Beukelman T, Lougee A, Matsouaka RA, Collier D, Rumsey DG, Schenfeld J, et al. Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry. Pediatr Rheumatol Online J. 2021 Aug 21;19(1):131.
Beukelman, Timothy, et al. “Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry.Pediatr Rheumatol Online J, vol. 19, no. 1, Aug. 2021, p. 131. Pubmed, doi:10.1186/s12969-021-00625-y.
Beukelman T, Lougee A, Matsouaka RA, Collier D, Rumsey DG, Schenfeld J, Stryker S, Twilt M, Kimura Y, CARRA Registry Investigators. Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry. Pediatr Rheumatol Online J. 2021 Aug 21;19(1):131.
Journal cover image

Published In

Pediatr Rheumatol Online J

DOI

EISSN

1546-0096

Publication Date

August 21, 2021

Volume

19

Issue

1

Start / End Page

131

Location

England

Related Subject Headings

  • United States
  • Tumor Necrosis Factor Inhibitors
  • Registries
  • Methotrexate
  • Medication Therapy Management
  • Male
  • Immunosuppressive Agents
  • Humans
  • Female
  • Etanercept